HIMS Stock Rises Overnight: Retail Traders Bet On Peptides Upside After FDA Panel Backs 6 Of 7 Compounds

An FDA advisory panel recommended approval of six out of seven peptides for inclusion on the 503A compounding list.

Emideltide was the only peptide rejected by the panel.

Retail traders are betting on HIMS stock upside due to the potential peptides market.

HIMS stock rose overnight following the news.